Algert Global LLC trimmed its position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 9.1% in the third quarter, HoldingsChannel.com reports. The firm owned 27,295 shares of the specialty pharmaceutical company’s stock after selling 2,739 shares during the period. Algert Global LLC’s holdings in ANI Pharmaceuticals were worth $1,543,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its holdings in shares of ANI Pharmaceuticals by 2.4% in the 1st quarter. Principal Financial Group Inc. now owns 68,687 shares of the specialty pharmaceutical company’s stock valued at $3,999,000 after acquiring an additional 1,630 shares during the last quarter. Piedmont Investment Advisors LLC bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $140,000. Aperio Group LLC lifted its holdings in shares of ANI Pharmaceuticals by 21.3% in the 2nd quarter. Aperio Group LLC now owns 5,799 shares of the specialty pharmaceutical company’s stock valued at $387,000 after acquiring an additional 1,019 shares during the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $235,000. Finally, Smith Asset Management Group LP lifted its holdings in shares of ANI Pharmaceuticals by 15.8% in the 2nd quarter. Smith Asset Management Group LP now owns 19,820 shares of the specialty pharmaceutical company’s stock valued at $1,324,000 after acquiring an additional 2,710 shares during the last quarter. Hedge funds and other institutional investors own 63.29% of the company’s stock.
Shares of NASDAQ ANIP opened at $53.50 on Friday. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $626.47 million, a price-to-earnings ratio of 14.82 and a beta of 2.54. ANI Pharmaceuticals Inc has a 1 year low of $48.40 and a 1 year high of $73.49.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.12. The business had revenue of $50.70 million during the quarter, compared to the consensus estimate of $50.97 million. ANI Pharmaceuticals had a net margin of 0.23% and a return on equity of 28.39%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.11 earnings per share. On average, sell-side analysts predict that ANI Pharmaceuticals Inc will post 4.54 earnings per share for the current fiscal year.
A number of brokerages recently commented on ANIP. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 22nd. Canaccord Genuity set a $70.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 9th. Cantor Fitzgerald set a $74.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 3rd. Finally, ValuEngine raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 23rd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $71.00.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/08/algert-global-llc-lowers-position-in-ani-pharmaceuticals-inc-anip.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Read More: Diversification
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.